[Conservative hormonal therapy for endometrial cancer]. 2004

Nobuyuki Susumu, and Daisuke Aoki, and Yutaka Tamada, and Koji Banno, and Atsushi Suzuki, and Nao Suzuki, and Shiro Nozawa
Department of Obstetrics & Gynecology, Keio University School of Medicine.

UI MeSH Term Description Entries
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006908 Hydroxyprogesterones Metabolites or derivatives of PROGESTERONE with hydroxyl group substitution at various sites.
D000077713 17 alpha-Hydroxyprogesterone Caproate Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS. 17 alpha-Oxyprogesterone Capronate,17-Hydroxyprogesterone Capronate,17-alpha-Hydroxy-Progesterone Caproate,Delalutin,Hydroxyprogesterone Caproate,Hydroxyprogesterone Hexanoate,Makena,Neolutin,Oxyprogesterone Caproate,Prolutin Depot,Proluton Depot,17 Hydroxyprogesterone Capronate,17 alpha Hydroxy Progesterone Caproate,17 alpha Hydroxyprogesterone Caproate,17 alpha Oxyprogesterone Capronate,Caproate, 17-alpha-Hydroxy-Progesterone
D016889 Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells. Cancer of Endometrium,Endometrial Cancer,Endometrial Carcinoma,Cancer of the Endometrium,Carcinoma of Endometrium,Endometrium Cancer,Neoplasms, Endometrial,Cancer, Endometrial,Cancer, Endometrium,Cancers, Endometrial,Cancers, Endometrium,Carcinoma, Endometrial,Carcinomas, Endometrial,Endometrial Cancers,Endometrial Carcinomas,Endometrial Neoplasm,Endometrium Cancers,Endometrium Carcinoma,Endometrium Carcinomas,Neoplasm, Endometrial
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017258 Medroxyprogesterone Acetate A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms. Depo-Medroxyprogesterone Acetate,Medroxyprogesterone 17-Acetate,Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6alpha)-,(6 alpha)-17-(Acetoxy)-6-methylpregn-4-ene-3,20-dione,6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate,Curretab,Cycrin,Depo-Provera,Farlutal,Gestapuran,Medroxyprogesterone 17-Acetate, (6 alpha,17 alpha)-Isomer,Medroxyprogesterone 17-Acetate, (6 beta)-Isomer,Perlutex,Provera,Veramix,6 alpha Methyl 17alpha hydroxyprogesterone Acetate,Depo Medroxyprogesterone Acetate,Depo Provera,DepoProvera,Medroxyprogesterone 17 Acetate
D018931 Antineoplastic Agents, Hormonal Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) Hormonal Antineoplastic Agents,Antineoplastic Drugs, Hormonal,Antineoplastic Hormonal Agents,Antineoplastic Hormonal Drugs,Antineoplastics, Hormonal,Hormonal Agents, Antineoplastic,Hormonal Antineoplastic Drugs,Hormonal Antineoplastics,Agents, Antineoplastic Hormonal,Drugs, Antineoplastic Hormonal,Hormonal Drugs, Antineoplastic

Related Publications

Nobuyuki Susumu, and Daisuke Aoki, and Yutaka Tamada, and Koji Banno, and Atsushi Suzuki, and Nao Suzuki, and Shiro Nozawa
July 1985, Harefuah,
Nobuyuki Susumu, and Daisuke Aoki, and Yutaka Tamada, and Koji Banno, and Atsushi Suzuki, and Nao Suzuki, and Shiro Nozawa
July 1985, Gan no rinsho. Japan journal of cancer clinics,
Nobuyuki Susumu, and Daisuke Aoki, and Yutaka Tamada, and Koji Banno, and Atsushi Suzuki, and Nao Suzuki, and Shiro Nozawa
December 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
Nobuyuki Susumu, and Daisuke Aoki, and Yutaka Tamada, and Koji Banno, and Atsushi Suzuki, and Nao Suzuki, and Shiro Nozawa
March 2005, European journal of cancer (Oxford, England : 1990),
Nobuyuki Susumu, and Daisuke Aoki, and Yutaka Tamada, and Koji Banno, and Atsushi Suzuki, and Nao Suzuki, and Shiro Nozawa
January 2013, Gynecologic and obstetric investigation,
Nobuyuki Susumu, and Daisuke Aoki, and Yutaka Tamada, and Koji Banno, and Atsushi Suzuki, and Nao Suzuki, and Shiro Nozawa
June 2008, Current oncology (Toronto, Ont.),
Nobuyuki Susumu, and Daisuke Aoki, and Yutaka Tamada, and Koji Banno, and Atsushi Suzuki, and Nao Suzuki, and Shiro Nozawa
January 2002, Zentralblatt fur Gynakologie,
Nobuyuki Susumu, and Daisuke Aoki, and Yutaka Tamada, and Koji Banno, and Atsushi Suzuki, and Nao Suzuki, and Shiro Nozawa
September 2022, La Revue du praticien,
Nobuyuki Susumu, and Daisuke Aoki, and Yutaka Tamada, and Koji Banno, and Atsushi Suzuki, and Nao Suzuki, and Shiro Nozawa
December 2010, The Cochrane database of systematic reviews,
Nobuyuki Susumu, and Daisuke Aoki, and Yutaka Tamada, and Koji Banno, and Atsushi Suzuki, and Nao Suzuki, and Shiro Nozawa
January 1990, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
Copied contents to your clipboard!